Physician profile
Jamii Johnson
NPI 1275888992
$5,401.97
in general payments reported to CMS, 2019-2025
21 companies · $910 in 2025
The $910 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $127 · 2021: $699 · 2022: $804 · 2023: $875 · 2024: $1,031 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792 · Education: $23.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.77 |
| Education | $23.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $656.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Vanda Pharmaceuticals INC. | $517.58 | 2024-2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $509.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $423.57 | 2019-2025 | |
| Amarin Pharma, INC. | $274.43 | 2019-2020 | |
| Allergan, INC. | $270.34 | 2019-2020 | |
| Indivior INC. | $261.33 | 2019-2023 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.63 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $223.23 | 2021-2023 | Verquvo |
| Axsome Therapeutics, INC. | $192.53 | 2025 | Auvelity |
| Lilly USA, LLC | $90.54 | 2022-2024 | Mounjaro |
| Lundbeck LLC | $63.56 | 2023-2025 | Rexulti |
| Alkermes, INC. | $57.77 | 2022 | |
| Glaxosmithkline, LLC. | $46.12 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.28 | 2020-2025 | Rexulti |
| Corcept Therapeutics | $31.44 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.08 | 2021 | |
| Amgen INC. | $17.45 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.20 | 2021 | |
| Pfizer INC. | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamii Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.